In addition, the same authors also associated the tumor mutation burden (TMB), which is an established marker of sensitivity to ICB, with a given EGFR mutation subtype, and found that EGFR Ex20ins mutations bear the lowest median levels of TMB (2.8 mutations/Mb in 19 evaluated patients) when compared with all other EGFR mutation subtypes, including common EGFR exon 19 deletion/L858R point mutations [10]. The gene discussed is EGFR; the disease is neoplasm.